TW200812617A - Veterinary method and composition - Google Patents

Veterinary method and composition Download PDF

Info

Publication number
TW200812617A
TW200812617A TW096115739A TW96115739A TW200812617A TW 200812617 A TW200812617 A TW 200812617A TW 096115739 A TW096115739 A TW 096115739A TW 96115739 A TW96115739 A TW 96115739A TW 200812617 A TW200812617 A TW 200812617A
Authority
TW
Taiwan
Prior art keywords
disclosed
cox
patent application
inhibitor
international patent
Prior art date
Application number
TW096115739A
Other languages
English (en)
Chinese (zh)
Inventor
Leopold Franz Goetze
Anthony Paul Ricketts
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TW200812617A publication Critical patent/TW200812617A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW096115739A 2006-05-04 2007-05-03 Veterinary method and composition TW200812617A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79816206P 2006-05-04 2006-05-04

Publications (1)

Publication Number Publication Date
TW200812617A true TW200812617A (en) 2008-03-16

Family

ID=38566286

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096115739A TW200812617A (en) 2006-05-04 2007-05-03 Veterinary method and composition

Country Status (4)

Country Link
JP (1) JP2007297385A (ja)
AR (1) AR060837A1 (ja)
TW (1) TW200812617A (ja)
WO (1) WO2007129169A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100922519B1 (ko) 2008-11-12 2009-10-20 대원제약주식회사 펠루비프로펜을 함유하는 용출률 및 안정성이 개선된 경구투여용 약제학적 제제
KR101561345B1 (ko) * 2013-10-17 2015-10-16 대원제약주식회사 제어방출되는 프로피온산 계열의 약제학적 조성물
JP6867000B2 (ja) * 2016-10-24 2021-04-28 国立研究開発法人農業・食品産業技術総合研究機構 受胎性促進剤

Also Published As

Publication number Publication date
WO2007129169A3 (en) 2008-03-20
AR060837A1 (es) 2008-07-16
JP2007297385A (ja) 2007-11-15
WO2007129169A2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
US5990148A (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US20040082543A1 (en) Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US20040147581A1 (en) Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
JPH11507669A (ja) シクロオキシゲナーゼ−２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
CA2603185A1 (en) Propane-1,3-dione derivative or salt thereof
SK138799A3 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
JPH11507670A (ja) シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
WO2004014430A1 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
CA2483785A1 (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
TW201607943A (zh) 作為ｅｐ４配體之新穎苯并咪唑衍生物
MXPA05004601A (es) Un procedimiento para el tratamiento, prevencion o inhibicion de un trastorno del snc y/o del dolor y de la inflamacion usando una combinacion de duloxetina, venlafaxina o atomoxetina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones de lo
JP2004521123A (ja) 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ
JP2007509968A (ja) 新形成を治療または予防するためのｈｓｐ９０阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ
TW200812617A (en) Veterinary method and composition
US20040053900A1 (en) Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
UA70294C2 (en) Use of cyclooxygenase-2 inhibitors as anti-angiogeuse of cyclooxygenase-2 inhibitors as anti-angiogenic agents nic agents
WO2004096206A2 (en) Therapeutic combination of a cox-2 inhibitor and a tace inhibitor
US20050187278A1 (en) Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20050143360A1 (en) Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
US20050085477A1 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia
US6440967B1 (en) Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E
JP7130180B2 (ja) 子宮内膜症の処置のためのインドールの新規誘導体
AU2007278431A1 (en) Annellated pyrrole compounds for cancer management
US20060252766A1 (en) Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
MXPA05006681A (es) Un metodo para el tratamiento, prevencion, o inhibicion de un desorden del cns y/o dolor e inflamacion, usando una combinacion de reboxetina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones de los mismos.